Phase II Study of Ivonescimab (PD1/VEGF Bispecific) and Cadonilimab???PDL1/CTLA4 Bispecific???in Combination with Etoposide and Carboplatin As First-line Therapy in Patients with Extensive Stage Small Cell Lung Cancer
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Cadonilimab (Primary) ; Ivonescimab (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jan 2025 New trial record